Hosted on MSN24d
Prothena outlines potential multi-billion dollar opportunity with birtamimab launch by 2026
Earnings Call Insights: Prothena Corporation plc (NASDAQ:PRTA) Q4 2024 Gene Kinney, President and CEO, emphasized Prothena's focus on addressing significant unmet medical needs through its ...
Hosted on MSN21d
Prothena Reports 2024 Financial Results and 2025 Outlook
Prothena Corporation ( (PRTA)) has released its Q4 earnings. Here is a breakdown of the information Prothena Corporation presented to its investors. Discover the Best Stocks and Maximize Your ...
Business Insider18d
Prothena price target raised to $110 from $94 at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Prothena (PRTA) to $110 from $94 and keeps an Overweight rating on the shares. The firm notes Prothena has multiple key ...
Business Insider23d
Prothena price target lowered to $20 from $24 at RBC Capital
RBC Capital lowered the firm’s price target on Prothena (PRTA) to $20 from $24 and keeps a Sector Perform rating on the shares. The company’s Q4 earnings reflected a pipeline whose timelines ...